

YaÅar ÑaliÅkan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9008329/publications.pdf>

Version: 2024-02-01

59
papers

1,373
citations

567281

15
h-index

361022

35
g-index

59
all docs

59
docs citations

59
times ranked

2366
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. <i>Nature Genetics</i> , 2014, 46, 1187-1196.	21.4	505
2	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. <i>Nature Communications</i> , 2020, 11, 1600.	12.8	120
3	Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1002-1009.	0.7	66
4	Genomic Mismatch at <i>LIMS1</i> Locus and Kidney Allograft Rejection. <i>New England Journal of Medicine</i> , 2019, 380, 1918-1928.	27.0	63
5	Osteoprotegerin/RANKL Axis and Progression of Coronary Artery Calcification in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 965-973.	4.5	61
6	Survey of US Living Kidney Donation and Transplantation Practices in the COVID-19 Era. <i>Kidney International Reports</i> , 2020, 5, 1894-1905.	0.8	54
7	The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy. <i>Kidney and Blood Pressure Research</i> , 2016, 41, 148-157.	2.0	38
8	Coronary artery calcification and coronary flow velocity in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2685-2690.	0.7	36
9	Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective?. <i>American Journal of Nephrology</i> , 2017, 46, 96-107.	3.1	36
10	Coronary flow reserve dysfunction in hemodialysis and kidney transplant patients. <i>Clinical Transplantation</i> , 2008, 22, 785-793.	1.6	32
11	Survey of current transplant center practices regarding COVID-19 vaccine mandates in the United States. <i>American Journal of Transplantation</i> , 2022, 22, 1705-1713.	4.7	32
12	Novel Biomarkers in Glomerular Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 205-216.	1.4	29
13	Type IV Collagen Mutations in Familial IgA Nephropathy. <i>Kidney International Reports</i> , 2020, 5, 1075-1078.	0.8	26
14	Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers. <i>Kidney360</i> , 2020, 1, 1291-1299.	2.1	25
15	Cardiac Biomarkers and Noninvasive Predictors of Atherosclerosis in Chronic Peritoneal Dialysis Patients. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 340-348.	2.0	20
16	Comparison of Markers of Appetite and Inflammation Between Hemodialysis Patients With and Without Failed Renal Transplants. , 2012, 22, 258-267.		19
17	Operational challenges in the COVID-19 era: Asymptomatic infections and vaccination timing. <i>Clinical Transplantation</i> , 2021, 35, e14437.	1.6	16
18	Plasma Ghrelin Levels Are Associated with Coronary Microvascular and Endothelial Dysfunction in Peritoneal Dialysis Patients. <i>Renal Failure</i> , 2009, 31, 807-813.	2.1	15

#	ARTICLE	IF	CITATIONS
19	Lower serum prohepcidin levels associated with lower iron and erythropoietin requirements in hemodialysis patients with chronic hepatitis C. <i>BMC Nephrology</i> , 2012, 13, 56.	1.8	15
20	Fabry Disease Prevalence in Renal Replacement Therapy in Turkey. <i>Nephron</i> , 2019, 142, 26-33.	1.8	14
21	Co-Deposition of IgM and C3 May Indicate Unfavorable Renal Outcomes in Adult Patients with Primary Focal Segmental Glomerulosclerosis. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 961-972.	2.0	13
22	Clinical significance of glomerular C3 deposition in primary membranous nephropathy. <i>Journal of Nephrology</i> , 2021, 34, 581-587.	2.0	11
23	The Effects of <i>Helicobacter pylori</i> Eradication on Proteinuria in Patients with Primary Glomerulonephritis. <i>International Journal of Nephrology</i> , 2014, 2014, 1-6.	1.3	10
24	Serum uric acid level is associated with cardiac hypertrophy in renal transplant recipients. <i>Clinical Transplantation</i> , 2011, 25, 368-374.	1.6	9
25	Evaluation of the Medically Complex Living Kidney Donor. <i>Journal of Transplantation</i> , 2012, 2012, 1-6.	0.5	8
26	LIMS1 risk genotype and T cell-mediated rejection in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2120-2129.	0.7	8
27	COVID-19 vaccination timing and kidney transplant waitlist management: An international perspective. <i>Transplant Infectious Disease</i> , 2022, 24, e13763.	1.7	8
28	Effect of pre-transplant dialysis modality on kidney transplantation outcome. <i>Peritoneal Dialysis International</i> , 2009, 29 Suppl 2, S117-22.	2.3	8
29	Evaluation of Genetic Kidney Diseases in Living Donor Kidney Transplantation: Towards Precision Genomic Medicine in Donor Risk Assessment. <i>Current Transplantation Reports</i> , 2022, 9, 127-142.	2.0	8
30	Variations of type IV collagen-encoding genes in patients with histological diagnosis of focal segmental glomerulosclerosis. <i>Pediatric Nephrology</i> , 2020, 35, 927-936.	1.7	7
31	Amyloid A Amyloidosis After Renal Transplantation: An Important Cause of Mortality. <i>Transplantation</i> , 2020, 104, 1703-1711.	1.0	7
32	Oxidative stress and macrophage infiltration in IgA nephropathy. <i>Journal of Nephrology</i> , 2022, 35, 1101-1111.	2.0	7
33	Biallelic variants in <i>TTC21B</i> as a rare cause of early-onset arterial hypertension and tubuloglomerular kidney disease. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2022, 190, 109-120.	1.6	6
34	Comparison of Renal Anastomosing Hemangiomas in End-Stage and Non-End-Stage Kidneys: A Meta-Analysis With a Report of 2 Cases. <i>International Journal of Surgical Pathology</i> , 2017, 25, 488-496.	0.8	4
35	Recurrent and de novo glomerulonephritis following renal transplantation: higher rates of rejection and lower graft survival. <i>International Urology and Nephrology</i> , 2017, 49, 2265-2272.	1.4	4
36	Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. <i>Clinical Transplantation</i> , 2020, 34, e14118.	1.6	4

#	ARTICLE	IF	CITATIONS
37	Approach to genetic testing to optimize the safety of living donor transplantation in Alport syndrome spectrum. <i>Pediatric Nephrology</i> , 2022, 37, 1981-1994.	1.7	4
38	<i>Serratia marcescens</i> , <i>Morganella morganii</i> , <i>Klebsiella oxytoca</i> related peritonitis attacks in a patient on automated peritoneal dialysis: A case report. <i>Nefrologia</i> , 2017, 37, 350-351.	0.4	3
39	Re-evaluation of glomerulitis using occlusion criteria based on the Banff 2013 revision: a retrospective study. <i>Transplant International</i> , 2017, 30, 579-588.	1.6	3
40	A case of immune complex mediated tubulointerstitial disease and nephrotic syndrome: anti LRP-2 Nephropathy with diffuse podocyte effacement. <i>Journal of Nephrology</i> , 2021, 34, 915-919.	2.0	3
41	Incidence, Clinical Correlates, and Outcomes of Pulmonary Hypertension After Kidney Transplantation: Analysis of Linked US Registry and Medicare Billing Claims. <i>Transplantation</i> , 2022, 106, 666-675.	1.0	3
42	Opioids and Kidney Transplantation. <i>Seminars in Nephrology</i> , 2021, 41, 42-53.	1.6	3
43	Clinician and patient attitudes toward use of organs from hepatitis C viremic donors and their impact on acceptance: A contemporary review. <i>Clinical Transplantation</i> , 2021, 35, e14519.	1.6	3
44	Long-Term Effects of Antibodies against Human Leukocyte Antigens Detected by Flow Cytometry in the First Year after Renal Transplantation. <i>Balkan Medical Journal</i> , 2013, 30, 37-45.	0.8	2
45	High Soluble CD30 Levels and Associated Anti-HLA Antibodies in Patients with Failed Renal Allografts. <i>International Journal of Artificial Organs</i> , 2016, 39, 547-552.	1.4	1
46	The effect of histopathologic and clinical features on allograft survival in renal transplant patients with antibody-mediated rejection. <i>Renal Failure</i> , 2017, 39, 19-25.	2.1	1
47	Case report: C3 glomerulopathy advancing atypical hemolytic uremic syndrome. <i>Nefrologia</i> , 2018, 38, 450-452.	0.4	1
48	Lower baseline eGFR levels and IgA nephropathy prediction tool. <i>Nephrology</i> , 2021, 26, 1026-1027.	1.6	1
49	Nephrotic syndrome developing in severe ovarian hyperstimulation syndrome. <i>International Journal of Fertility & Sterility</i> , 2014, 7, 345-8.	0.2	1
50	SP127THE CLINICAL SIGNIFICANCE OF PLA2R ANTIBODIES AND C3 DEPOSITION IN THE PROGRESSION OF MEMBRANOUS NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i128-i128.	0.7	0
51	MP324CONSANGUINITY ASSOCIATED KIDNEY DISEASES IN ADULT TURKISH POPULATION. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i446-i447.	0.7	0
52	MP516OUTCOME AND RISK FACTORS FOR MORTALITY IN PERITONEAL DIALYSIS PATIENTS: 20 YEARS EXPERIENCE IN A SINGLE TURKISH CENTER. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i511-i512.	0.7	0
53	MP695RECURRENT GLOMERULAR DISEASES AND ALLOGRAFT REJECTION. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i570-i571.	0.7	0
54	SP690LONG-TERM OUTCOMES OFKIDNEY TRANSPLANTATIONIN GENETIC DISEASES. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i578-i579.	0.7	0

#	ARTICLE	IF	CITATIONS
55	SP148THE EFFECT OF BIOMARKERS AND OXFORD CLASSIFICATION ON PROGRESSION OF Ig A NEPHROPATHY. Nephrology Dialysis Transplantation, 2018, 33, i394-i394.	0.7	0
56	SP181COMPARISON OF VARIOUS FEATURES AND OUTCOMES IN ADULT PATIENTS WITH IMMUNE COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS AND C3 GLOMERULOPATHY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
57	SP184EFFICACY OF ECULIZUMAB IN PATIENTS WITH REFRACTORY C3 GLOMERULONEPHRITIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
58	SP782EFFECTS OF A STANDARDIZED TREATMENT APPROACH ON KIDNEY TRANSPLANT RECIPIENTS WITH ANTIBODY-MEDIATED REJECTION. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
59	SP196EFFICACY OF RITUXIMAB IN ADULT PATIENTS WITH REFRACTORY PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0